| Friday, April 26, 2024  A single injection of an experimental monoclonal antibody called L9LS prevented malaria infection in children in Mali. L9LS binds to and neutralizes "sporozoites," the form of the malaria parasite transmitted by mosquitoes that invades the liver to initiate infection. Credit: NIH One injected dose of an experimental malaria monoclonal antibody developed by NIAID was 77% effective against malaria disease in children in Mali during the country's six-month malaria season, according to results published in The New England Journal of Medicine. Study authors say the Phase 2 trial results demonstrated for the first time that a single dose of a monoclonal antibody given by subcutaneous injection can provide high-level protection against malaria in children in an area of intense malaria transmission. The trial assessed L9LS in two dose levels, with 19% of the 300mg-dose group and 28% of the 150mg-dose group developing symptomatic malaria, providing protective efficacy of 77% and 67% against symptomatic malaria, respectively. Among children who received placebo, 81% became infected with Plasmodium falciparum, and 59% had symptomatic malaria during the six-month study period. The researchers are continuing clinical development of L9LS, focusing on other high-risk populations, such as infants and young children, children hospitalized with severe anemia, and pregnant women. National Institute of Allergy and Infectious Diseases | National Institutes of Health | | | |
No comments:
Post a Comment